MedinCell S.A. (MDCLF)
| Market Cap | 1.21B -0.3% |
| Revenue (ttm) | 27.99M -12.4% |
| Net Income | -36.07M |
| EPS | -1.06 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 620 |
| Open | 30.26 |
| Previous Close | 34.39 |
| Day's Range | 30.26 - 30.26 |
| 52-Week Range | 30.26 - 34.39 |
| Beta | 0.92 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 9, 2026 |
About MedinCell
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of po... [Read more]
Financial Performance
In fiscal year 2026, MedinCell's revenue was 24.28 million, a decrease of -12.44% compared to the previous year's 27.73 million. Losses were -31.29 million, 69.7% more than in 2025.
Financial numbers in EUR Financial StatementsNews
MedinCell downgraded to Hold from Buy at Kepler Cheuvreux
Kepler Cheuvreux downgraded MedinCell (MDCLF) to Hold from Buy with a EUR 31 price target
Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext: MEDCL) announces that, for operational reasons, the publication of its half-year financial results (April 1st –September 30, 2026) has been r...
Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced that it has secured an additional €13.8 million in non-dilutive financing from leading European commercial banks...
MedinCell Transcript: Investor update
WELTRUZA’s U.S. approval adds a second long-acting product and potential royalty stream, targeting oral olanzapine patients without post-injection monitoring. Teva estimates up to $2B in combined peak sales for WELTRUZA and UZEDY, while pipeline and BEPO Star development remain priorities.
MedinCell Press release: Investor update
MedinCell issued a press release on October 9, 2026, disclosing material business information to investors.
Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL) Medincell will host Investor webcast today to discuss the implications of the approval for the Company and answer questions from analysts....
MedinCell initiated with an Outperform at Oppenheimer
Oppenheimer analyst Les Sulewski initiated coverage of MedinCell (MDCLF) with an Outperform rating and EUR 35 price target
Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
MONTPELLIER, France--(BUSINESS WIRE)--Medincell's partner Teva presented new data on investigational Olanzapine long-acting injectable (LAI) and UZEDY®, two treatments utilizing Medincell's proprietar...
Medincell to Participate in Upcoming Investor Conferences
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announ...
Medincell: Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): The Annual General Meeting and Extraordinary General Meeting will be held at Medincell's headquarters (3 rue des Frères ...
Medincell Appoints Edna Venneker, MD, as Chief Medical Officer
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext: MEDCL), a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple the...
Medincell's Dr Grace Kim to Participate in Piper Sandler CNS Symposium
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable tr...
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a recor...
Medincell Continues to Strengthen and Renew its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced that its Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at...
Medincell Aligns Debt Maturity with Its Expected Revenue Growth Trajectory
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced the completion of non-dilutive financing transactions designed to strengthen its financing profile and align deb...
MedinCell Slides: Corporate presentation
MedinCell has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
MedinCell Transcript: H2 25/26
Strong royalty growth from UZEDY and pipeline expansion drove recurring revenues, despite a net loss due to increased R&D and business development investments. Olanzapine LAI is on track for a late 2026 launch, with meaningful revenues expected in 2027.
MedinCell Earnings release: H2 2026
MedinCell released its H2 2026 earnings on June 16, 2026, summarizing the period's financial results.
MedinCell Slides: H2 2026
MedinCell has posted slides in relation to its H2 2026 quarterly earnings report, which was published on June 16, 2026.
MedinCell Annual report: H2 2026
MedinCell has published its H2 2026 annual report on June 16, 2026.
Medincell Reports FY 2025-26 Annual Results
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): Key Financial Highlights Total revenues €24.3 million, including €9.3 million of UZEDY® royalties, confirming the evolution of the reve...
MedinCell Transcript: Jefferies Global Healthcare Conference 2026
Long-acting injectable products are driving rapid revenue growth, with UZEDY outperforming forecasts and olanzapine LAI poised for approval and launch later this year. Strategic partnerships, a robust pipeline, and next-generation technology underpin a catalyst-rich outlook for 2026.
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announ...
Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatme...
MedinCell Transcript: R&D Day 2026
Strong adoption of UZEDY and anticipated approval of olanzapine LAI validate the platform approach, while strategic partnerships and robust IP drive long-term royalty growth. Platform innovation and lifecycle management strategies expand opportunities in chronic diseases and beyond.